Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City
Transgender women may face a disparate risk for HIV/AIDS compared to other groups. In 2012, Truvada was approved for daily use as HIV pre-exposure prophylaxis (PrEP). However, there is a dearth of research about barriers and facilitators to PrEP in transgender women. This paper will shed light on transgender women living in New York City’s perceived and actual challenges to using PrEP and potential strategies to overcome them. After completing an initial screening process, four 90-min focus groups were completed with n = 18 transgender women. Participants were asked what they like and dislike about PrEP. Participants identified the following barriers: uncomfortable side effects, difficulty taking pills, stigma, exclusion of transgender women in advertising, and lack of research on transgender women and PrEP. Facilitators included: reducing pill size, increasing the types of available HIV prevention products, and conducting scientific studies to evaluate PrEP in transgender women.
KeywordsTransgender women Transwomen PrEP HIV prevention Barriers Facilitators
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. The research team would like to thank all participants for their time, hard work, and critical insight.
Compliance with Ethical Standards
Conflict of interest
All authors declare that they have no conflicts of interest.
All procedures performed in this study involving human participants were in accordance with the ethical standards of the Institutional Review Board, Human Subjects Committee of the New York State Psychiatric Institute and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
- 1.US Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2012.Google Scholar
- 10.Dowshen N, Lee SS, Castillo M, Hawkins L, Barg FK. Barriers and facilitators to HIV prevention, testing, and treatment among young transgender women. J Adolesc Health. 2016;58(2):S81–2.Google Scholar
- 14.SFDPH. San Francisco Department of Public Health. https://www.sfdph.org/dph/default.asp (2017). Accessed 2 Apr 2017.
- 15.Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDS. 2013;27(4):248–54.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Galindo GR, Walker JJ, Hazelton P, Lane T, Steward WT, Morin SF, et al. Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation. Implement Sci. 2012;7:116.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Dunne N. Northwestern receives $17 million grant for HIV prevention research: Northwestern Medicine: Feinberg School of Medicine. (2015). http://news.feinberg.northwestern.edu/2015/08/17-million-grant-for-hiv-prevention-research/.
- 20.aidsinfo.nih.gov. Cabotegravir: U.S. Department of Health and Human Services. (2017). https://aidsinfo.nih.gov/drugs/513/cabotegravir/0/patient.
- 21.Saldaña J. The coding manual for qualitative researchers. 2nd ed. London: Sage; 2013.Google Scholar
- 22.Greene JA, Thorogood N. Qualitative methods for health research: Third edition. Silverman D, editor. London: Sage; 2014.Google Scholar
- 28.Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2013;381(9883):2083–90.CrossRefGoogle Scholar
- 31.Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV Pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2013;17(6):2162–72.CrossRefPubMedPubMedCentralGoogle Scholar
- 37.HPTN-083. A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men. https://www.hptn.org/research/studies/hptn083 (2017). Accessed 2 April 2017.
- 44.Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, See SJ, Leibowitz AA. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care. 2011;23(9):1136–45.CrossRefPubMedPubMedCentralGoogle Scholar
- 45.DOHMH. New York City Department of Health and Mental Hygiene: prevent HIV and other STIs. http://www1.nyc.gov/site/doh/health/health-topics/playsure.page (2017). Accessed 17 July 2017.
- 46.DOHMH. New York City Department of Health and Mental Hygiene: be sure, play sure, stay sure. https://www1.nyc.gov/site/doh/health/health-topics/hiv-besure-playsure-staysure.page (2017). Accessed 18 July 2017.